Search

Your search keyword '"Marcantoni, Carmelita"' showing total 147 results

Search Constraints

Start Over You searched for: Author "Marcantoni, Carmelita" Remove constraint Author: "Marcantoni, Carmelita"
147 results on '"Marcantoni, Carmelita"'

Search Results

2. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

3. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

4. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

5. SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)

7. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

8. Association of obesity with 3-month mortality in kidney failure patients with COVID-19

9. α- and β-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy

10. alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy.

11. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis

12. Calculation of Kidney Volumes with Magnetic Resonance in Patients with Autosomal Dominant Polycystic Kidney Disease: Comparison between Methods.

13. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

14. Previous therapy with immune checkpoint inhibitor as a cause of hypothyroidism, myositis, and renal insufficiency in a candidate for allogeneic hematopoietic transplantation

15. COVID-19-related mortality in kidney transplant and haemodialysis patients

16. Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy

19. Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19

20. GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy

33. Renin-Angiotensin System Blockers and the Risk of COVID-19–Related Mortality in Patients with Kidney Failure

37. Prevalence of renal artery stenosis in patients undergoing cardiac catheterization

38. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens

40. Incorporating Glomerular filtration rate or creatinine clearance by the modification of diet in renal disease equation or the Cockcroft–Gault equations to improve the Global Accuracy of the Age, Creatinine, Ejection Fraction [ACEF] score in patients undergoing percutaneous coronary intervention

41. Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial

45. α- and β-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy

Catalog

Books, media, physical & digital resources